NCCIT(人畸胎瘤细胞)
CBP61089
询 价
索取STR
产品描述
产品数据库
I. General information | |
Synonyms: | NCCIT |
Background: | NCCIT was established by Shinichi Teshima (National Cancer Institute, Tokyo, Japan) in 1985 from a mediastinal mixed germ cell tumor. |
Species: | Homo sapiens, human |
Tissue: | anterior mediastinal mixed germ cell tumor |
Disease: | pluripotent embryonal carcinoma; teratocarcinoma |
Gender: | male, adult, Japanese |
Morphology: | epithelial |
Growth Mode: | adherent |
Doubling Time: | N/A |
DNA Profile: | Amelogenin: X CSF1PO: 10,12 D13S317: 11 D16S539: 9,12 D5S818: 10,13 D7S820: 10 THO1: 7,9 TPOX: 8 vWA: 14,18 Cobioer’s Cell Line Authentication Service |
Culture Medium: |
RPMI 1640+10% FBS NCCIT完全培养基,# CBP61089M |
Cryopreservation medium: | 90%FBS+10%DMSO |
Antigen Expression: | N/A |
Receptor Expression: | N/A |
Oncogene: | N/A |
Genes Expressed: | N/A |
Cellular Products: | N/A |
Tumor Formation: | Yes, Tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 107 cells. |
Comments: | This pluripotent stem cell line is capable of somatic and extraembryonic differentiation. The undifferentiated cells are equivalent to a stage intermediate between seminoma and embryonal carcinoma. They will differentiate in response to retinoic acid. NCCIT cells are negative for keratin. They are positive for vimentin and placental alkaline phosphatase. The line was contaminated with mycoplasma, but was cured by the depositor prior to deposit at the ATCC. For more information, please contact Cobioer (4008-750-250). |